^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer
Published date:
02/03/2021
Excerpt:
Innovent Biologics, Inc....today jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) of TYVYT® (sintilimab injection) in combination with pemetrexed and platinum chemotherapy as first-line therapy for people with nonsquamous non-small cell lung cancer (nsqNSCLC).
Secondary therapy:
pemetrexed
Source:
Title:
Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12)
Published date:
05/25/2021
Excerpt:
In terms of PFS, sintilimab plus GP demonstrates clinical benefit over GP alone as first-line therapy in patients with locally advanced or metastatic sqNSCLC.
Secondary therapy:
gemcitabine
DOI:
10.1016/j.jtho.2021.04.011
Trial ID:
Title:
Innovent and Lilly Release Clinical Trial Results of Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous NSCLC in an Oral Presentation at IASLC WCLC 2020 Virtual Presidential Symposium
Published date:
08/08/2020
Excerpt:
Based on the interim analysis conducted by the Independent Data Monitoring Committee (IDMC), TYVYT® (sintilimab injection) in combination with ALIMTA® (pemetrexed) and platinum chemotherapy demonstrated a statistically significant improvement in progression-free survival (PFS)...
Secondary therapy:
pemetrexed
Trial ID:
